Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Yet the long-term growth potential of healthcare can’t be ignored — the sector accounts for 10.2% of global GDP and with the global GDP projected to reach $137 trillion by 2030, there will be some $14 ...

VALENCIA, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...

Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies. Click here to find out why I ...

The U.S. Food and Drug Association (FDA) released the first-ever guidelines for levels of lead in processed baby foods ...

For the second year in a row, 2024 was a banner year for the regulation of per- and polyfluoroalkyl substances (PFAS) at the federal level.

Dual-listed regenerative medicine company Avita Medical has seen its share price slide ~19% today on a downgrade of its ...

With multiple stakeholders involved with different interests, the “specialty drug” definition can be a moving target.

High Q Technologies today announced the commercial availability and first sale of FATHOM, a class-leading and innovative EPR ...

Alnylam's TTR franchise, powered by Amvuttra, poised for $7.5B peak revenue with undervalued shares and long-term growth ...